Compare COYA & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COYA | BGX |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 151.0M |
| IPO Year | 2022 | N/A |
| Metric | COYA | BGX |
|---|---|---|
| Price | $5.97 | $11.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.80 | N/A |
| AVG Volume (30 Days) | ★ 192.0K | 67.9K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,987,706.00 | N/A |
| Revenue This Year | $88.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $10.69 |
| 52 Week High | $8.29 | $12.44 |
| Indicator | COYA | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 51.19 |
| Support Level | $6.00 | $11.77 |
| Resistance Level | $6.44 | $11.90 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.70 | 83.70 |
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.